2bPrecise Honored as One of Israel’s Top Startups
2bPrecise™, LLC, was named one of nine finalists in Israel’s “most promising startup” competition. Sponsored by Calcalist, Israel's leading financial daily news publication, the contest drew more than 50 nominations.
“We are honored to be included with this elite group,” said 2bPrecise founder and CEO Assaf Halevy. “Although a small country, Israel is recognized as home to some of the most powerful innovations and technologies. It is gratifying to know we are considered among the most promising young companies in the region.”
Along with eight other finalists, Halevy presented the 2bPrecise precision medicine business model and technology platform Monday, Oct. 29, to a panel of 10 judges at Calcalist’s eighth annual digital and mobile conference, INSPIRE Digital@Mobile. Papaya Global Ltd., which automates payroll processing, labor law compliance and other human resource activities, was selected as the top startup following the presentations Monday.
2bPrecise was established in 2015 with the objective of bridging the final mile between the science of genomics and making that data useful at the point of care. Leadership assembled a team with deep experience with complex ontologies and clinical integration to create a cloud-based platform that delivers previously inaccessible genomic data within the patient context.
Owned by Allscripts Healthcare Solutions, the company is headquartered in Be’er Sheva, Israel, with U.S. offices in Pittsburgh.
ABOUT 2bPRECISE, LLC
The 2bPrecise precision medicine platform harnesses the power of genomics to help healthcare providers identify patients at risk for disease, and more effectively determine optimal preventive, diagnostic and therapeutic care. Vendor-agnostic and cloud-based, 2bPrecise consumes data from any lab or knowledge source and delivers it into the clinical workflow of any EHR, in an actionable format and in a vocabulary meaningful to clinicians. Its robust data model future-proofs the solution and enables clients to customize their strategic precision medicine strategy, starting where it makes most sense for them and scaling across the entire enterprise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005146/en/